Human papillomavirus (HPV) vaccination uptake (initiation and completion): factors associated with uptake of the human papillomavirus (HPV) vaccine among young people living with HIV in Uganda Authors: Scovia Nalugo Mbalinda, Aggrey Semeere, Derrick Amooti Lusota, Jean Hunleth, Michelle Silver, Dan Kabonge Kaye, Miriam Nakalembe Published: 2026 ABSTRACT AbstractIntroductionThe prevalence of human papillomavirus (HPV) infection and related illnesses is disproportionately high in women and young people living with HIV. Vaccination against high-risk HPV types has the potential to reduce HPV- associated disease burden dramatically. However, HPV vaccine uptake has been variable and suboptimal in most countries, including Uganda, with low levels of both initiation and completion of the HPV doses. The purpose of this research was to identify determinants of HPV vaccine uptake and completion among young girls living with HIV.MethodsA cross-sectional study was conducted among 274 adolescents and young people living with HIV who were selected from an antiretroviral therapy (ART) clinic in a district Hospital ART clinic, Uganda. Data were collected between February and June 2024. The data were collected using a structured questionnaire examining HPV vaccine uptake (initiation and completion). Bivariate and multivariate analyses were conducted to assess factors associated with HPV vaccine uptake using SPSS version 21 software.ResultsThis study involved 274 participants, with a mean age of 20.3 years ranging from 15-24 years. The proportion who initiated HPV vaccination in this study was 68.2% (187/274), and HPV vaccine dose completion (2 doses and more) was 24.1% (66/274). The uptake of HPV vaccination was significantly associated with age 15 to 19 years (AOR 2.9, 95% CI 1.352-6.1 P = 0.006), having been taught about HPV vaccine and cervical cancer at school (AOR 8.7 95% CI 2.8–24.7, P = < 0.001), living within a distance of less than 5 km from the health facility (AOR 5.9, 95% CI 2.2–16.1, P = < 0.001), and availability of HPV vaccines at the health facility (AOR 5.2, 95% CI 1.9–14.5, P = < 0.001). The completion of HPV vaccination was significantly associated with age 20 to 24 years (AOR 1.9, 95% CI 1.057–3.499, P = 0.032).ConclusionThe initiation and completion of HPV vaccination among HIV- positive girls are both crucial for preventing HPV related diseases and cancers. In this study, the completion rate is very low. Vaccination against human papillomavirus (HPV) must be prioritised in the HIV-positive youth population. The findings suggest a need for targeted policies to improve vaccine uptake among HIV-positive youth, including better education, healthcare provider engagement, and system support for follow-up care. This will guide targeted interventions in achieving the WHO’s target of 90% immunising all adolescent girls by 2030.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12913-026-15035-7.Keywords: HPV, HPV vaccination, Adolescents, HIV-positive, Young people Introduction Globally, cervical cancer, a malignancy caused by the human papillomavirus(HPV), ranks fourth in terms of frequency among women [1]. In 2022, globally there were to be an estimated 660,000 new cases and 350,000 fatal cases [1]. Low- and middle-income countries (LMICs) have the highest incidence and mortality rates from cervical cancer [2]. With an age-standardized incidence rate of 47.5 per 100,000 and a mortality rate of 25 per 100,000, Uganda has some of the highest rates of cervical cancer worldwide in terms of both incidence and mortality [3, 4]. The burden of HPV infections and cervical cancer worldwide adds to the impact that HIV has on women, especially young women and adolescent girls from LMICs [5]. A comprehensive analysis of the HPV prevalence in sub-Saharan Africa revealed that women living with HIV (WLWH) had a much higher HPV prevalence of 54% and a higher rate of co-infections [6]. HIV-positive women had a greater prevalence of any HPV infection or multiple HPV infections (53.6/22.6%) compared to HIV-negative women (26.5/7.3%) [7]. HIV-positive individuals are more likely than HIV-negative individuals to get HPV infections, diseases, and malignancies associated with HPV [8–11]. The HPV vaccine is highly effective at preventing HPV infections that can lead to cervical cancer and other HPV-related cancers [12]. The HPV vaccine effectively prevents cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancer infections [13, 14], providing strong protection for at least 10–11 years [15]. World Health Organization (WHO) recommends at least two doses of HPV vaccination (with a minimum 6-month gap) and, if feasible, three doses should be administered to people known to be immunocompromised or HIV-positive (independent of age or use of antiretroviral medication) [16]. The best time to deliver the HPV vaccine is prior to the start of sexual activity. Research shows that many teenagers start having sex by the time they are 14 years old; thus getting vaccinated early is essential to maximizing protection against HPV [17–19]. Immune responses to vaccination in HIV-positive individuals are frequently suboptimal. However, although they can improve with antiretroviral therapy (ART), they often stay lower and diminish more quickly than in HIV-negative individuals [8–11]. In Uganda, HPV vaccination was launched in 2015, and the 2-dose HPV vaccine series has since been integrated into the Uganda National Expanded Program on Immunisation [17] (UNEPI) by adopting two strategies, the school-based approach and the static (with selected outreach) routine immunisation services and focusing on young girls aged 9–14 [20]. However, current WHO guidelines have acknowledged the effectiveness of administering a single dose of HPV vaccine and have advised revising the dosage schedules to provide countries with the option to provide either one or two doses to girls aged 9–14 years, and at least two doses or more for immunocompromised individuals, including adolescent girls living with HIV [21]. Uganda is yet to adopt these strategies. In Uganda, the uptake of HPV vaccines is still below average, with notable differences observed between various areas and demographic groups. Low HPV vaccination uptake among school girls in Lira City, Uganda, at 19.3%, is linked to school education, clinic exposure, and health worker recommendations [22, 23]. A survey of young women in Lake Victoria fishing communities revealed low HPV vaccine uptake, attributed to factors like limited awareness, frequent mobility, and school absenteeism [23]. A 2016 Uganda Demographic and Health Survey revealed that 78% of adolescent girls aged 10–14 had not received HPV vaccination, with factors like school attendance, age, ethnicity, and socioeconomic status influencing vaccination uptake [24]. There is limited information available about the uptake and completion of the HPV vaccine, as well as associated factors, among young female people living with HIV. Theoretical framework Several theoretical frameworks guided the study of factors influencing HPV vaccination uptake in Uganda. The Health Belief Model (HBM), focusing on perceived vulnerability, severity, advantages, obstacles, action cues, and self-efficacy, provided a robust framework for understanding and addressing these factors [25]. The HBM provided a framework for examining the beliefs and perceptions influencing individuals’ decisions to receive the HPV vaccine. The Risk Information Seeking and Processing for Prevention (RISP) model offered a comprehensive understanding of how individuals process information about HPV vaccination, considering factors such as risk perceptions, information sufficiency, and social norms [26]. This model helped understand the factors influencing vaccination intentions and behaviours. Andersen’s Behavioral Model, a well-established model in the field, further enhanced the scientific rigour of the research, providing a comprehensive understanding of the behavioural factors influencing HPV vaccination uptake [27]. Materials and methods Study design and setting This was a cross-sectional study of adolescents and young girls living with HIV attending the Mityana General Hospital ART clinic. Data were collected from February 2024 to June 30, 2024. Study site The study was conducted at Mityana General Hospital. Mityana General Hospital is located in the town of Mityana, Mityana District, in the Central Region of Uganda, about 85 km (53 mi) East of Mubende Regional Referral Hospital, the regional referral hospital, and approximately 69 km (43 mi) west of Mulago National Referral Hospital, the largest hospital in the country. Study population Youngs females living with HIV were selected from the adolescent ART clinic through a consecutive sampling procedure. At the site, the research assistants recruited all the available participants in the ART clinic. They enrolled those who fulfilled the inclusion criteria (aged 15 to 24 years, provided informed consent or assent, not sick to consent and exclusion criteria not present at the ART clinic at the time of data collection until the sample size was obtained. Sample size determination We used the Kish Leslie sample size determination formula, assuming a prevalence of 22% [21] and a margin of error of 5% at a 95% confidence interval. The sample size was 255 respondents. On adjusting for non-response, at a rate of 10%, the final calculated sample size was 280 respondents. However, during data collection, we were able to enroll 272 (97.2%) respondents. Variables and measurements As a dependent variable, HPV vaccine uptake (i.e., initiating and completing the vaccine) was measured by having a vaccination card that shows the number of doses received and the memory of getting an injection on the left upper arm if the child was 9–15 years old. Initiation was defined as receiving at least one of the recommended two- or more-dose series of the HPV vaccine, and completion was defined as receiving or completing two or more doses of the vaccine. Independent variables in this study included socio-demographic factors (e.g., age, religion, tribe, main caregiver education level, and employment status), health system factors (e.g., availability of vaccines, accessibility to health facilities, etc.), and knowledge, attitudes, and information about HPV vaccination. Data were collected through face-to-face interviewer-administered questionnaires in a private room. This questionnaire was developed from the literature and adopted for this study. The data collected from participants included socio-demographic characteristics (age, religion, tribe, main caregiver, education level and status, employment status of caregiver), knowledge about HPV vaccination, attitudes towards HPV vaccination, information on HPV vaccination, uptake and factors affecting the uptake of HPV vaccination among adolescents. Data management and analysis The data was collected using Kobo Collect v2023.2.4 and later exported into Excel 2016. The Excel file was exported to SPSS version 21 software for analysis. The mean, median, frequency tables, and standard deviations of continuous variables were derived at univariate analysis. The proportion of those who initiated and completed HPV vaccination was computed as the number of participants with evidence of vaccination cards indicating the number of HPV vaccines received over the total participant population. To assess factors associated with the initiation and completion of the HPV vaccine, we utilized Pearson’s chi-square test for categorical explanatory factors, and the student t-test for continuous explanatory variables. The variables that were found statistically significant in bivariate analysis with a p-value of less or equal to 0.05 were considered for multivariate logistic regression. Analyses were done using SPSS version 21. Stepwise logistic regression models were built to identify independent predictors for initiating and completing the HPV vaccine. During model development, all predictor variables with a p-value of ≤ 0.2 at bivariate analysis were considered for inclusion in the multivariate logistic regression model. Collinearity was assessed using a correlation matrix and cross-checked using the variance inflation factor set at 10. In case two variables were associated (P < 0.05), the variable explaining the largest variability (smaller P-value at univariate analysis) was retained. Significance was set at 0.05, and all of the analyses were two-tailed. Quality assurance The research team was trained, and research tools were pre-tested among facilities not included in the study; this provided clarity, relevance, and comprehension of the tool and experienced research assistants were used as part of the quality assurance methods. Field supervision initiatives ensured the collection of high-quality data through coordinating the activities of their team, reporting progress, and addressing any issues that may arise in a timely manner daily supervision and spot checks by field supervisors can help identify and rectify any inconsistencies or incomplete data at the time of collection. The research team was the only one with access to the participants’ data, which was securely stored. The data collection tool was translated to the local language (Luganda). to ensure enhanced data quality, reduced data loss, inclusivity by reaching non-native speakers, and equity in research by ensuring all segments can participate. This approach respects cultural diversity, builds trust, and results in honest responses, providing reliable data collection. Ethics approval and consent to participate Ethical reviews and approval were obtained from the Research Ethics Committee of the School of Health Sciences, College of Health Sciences at Makerere University (#MAKSHSREC-2023-611) and the Uganda National Council for Science and Technology (HS3685ES). Administrative clearance and permissions were also obtained from the management of Mityana General Hospital. Written informed consent was obtained from young people 18 years and above. For adolescents below 18 years, consent from the parents/guardians and subsequently assent from the adolescents was obtained. Participation was voluntary, and all the interviews were conducted in private settings to ensure the confidentiality of the participants, and participation was voluntary. Results Socio‑demographic characteristics of the participants A total of 274 (97.2%) participants were enrolled between February and June. The mean age of participants was 20.32 years (SD = 2.8), with an age range of 15–24 years. Most participants, 123 (44.9%), were Catholics by religion and were from the Baganda tribe, 217 (79.2%). Of the participants, 169 (61.7%) lived with their parents, 164 (59.9%) were currently out of school, and 110 (40.1%) were still in school. When asked about their level of education, 163 (59.5%) had secondary education, 81 (29.6%) had completed primary education, 11 (4.0) had completed tertiary education, and 19 (6.9%) had no education. 247 (90.1%) of the participants had employed caregivers, and 192 (70.1%) resided in urban settings. See Table 1 below. Table 1Socio-demographic characteristics of the participantsVariableFrequency (n = 274)Percentage (%) Age (Mean 20.32, standard deviation 2.815 ReligionCatholicAnglicanBorn againMuslim12365592744.923.721.59.9 Tribe MugandaOther2175779.220.8 With whom are you staying with? With parentsOthers16910561.738.3 Family type at household level Nuclear familyExtended family1878768.231.8 Current education status At schoolOut of school11016440.159.9 level of education finished No educationPrimary educationSecondary educationTertiary education1981163116.929.659.54.0 Residence UrbanRural1928270.129.9 Employment status of caretaker EmployedUnemployed2472790.19.9 Socio-demographic characteristics of the participants Religion Catholic Anglican Born again Muslim 123 65 59 27 44.9 23.7 21.5 9.9 Muganda Other 217 57 79.2 20.8 With parents Others 169 105 61.7 38.3 Nuclear family Extended family 187 87 68.2 31.8 At school Out of school 110 164 40.1 59.9 No education Primary education Secondary education Tertiary education 19 81 163 11 6.9 29.6 59.5 4.0 Urban Rural 192 82 70.1 29.9 Employed Unemployed 247 27 90.1 9.9 Uptake and completion of the HPV vaccine among female adolescents living with HIV/AIDS attending the ART clinic The HPV vaccine was administered to more than half of the participants, 187 (68.2%) of whom 121 (64.7%) had received one dose, 42 (22.5%) had received two doses, and 24 (12.8%) had received three doses. When asked about where they received the HPV vaccines from, most of the participants reported schools 157 (84.0%) for the first dose, 53 (80.3%) for the second dose, and 20 (83.3%) for the third dose. The proportion of HPV vaccine uptake in this study was 68.2% (187/274), and HPV vaccine dose completion was 24.1% (66/274). See Table 2 below. Table 2Knowledge, information, and uptake of HPV vaccine among female adolescents living with HIV/AIDS attending a district Hospital ART clinicVariableFrequency (n)Percentage (%) Knowledge about HPV vaccine Ever heard of HPV Vaccine (n = 274)YesNo1829266.433.6HPV vaccine is used to prevent Human papillomavirus infection and cervical cancer (n = 182)YesNoI don’t know14982581.94.413.7Recommended dose of HPV vaccine (n = 182)One dosTwo dosesI don’t know89494448.926.924.2The ideal time HPV vaccine best recommended (n = 182)Less than 9 years9–14 yearsCan be provided at any ageI don’t know1966534410.436.329.124.2 Information about HPV vaccine Ever received information about HPV vaccine.YesNO13813650.449.6Ever been taught about HPV or cervical cancer at schoolYesNo11915543.456.6Availability of awareness creation about cervical cancer or HPV vaccine at school or communityYesNo14712753.646.4Need more information about HPV Vaccination.YesNo2611395.34.7 Uptake and completion of HPV vaccination Have you received the HPV Vaccine? (n = 274)YesNo1878768.231.8If YES, how many doses? (n = 187)1 dose2 doses3 doses121422464.722.512.8HPV vaccine completion (n = 274)YesNo6620824.175.9HPV vaccine completion among those vaccinated (n = 121)YesNo665554.545.5 Knowledge, information, and uptake of HPV vaccine among female adolescents living with HIV/AIDS attending a district Hospital ART clinic Yes No 182 92 66.4 33.6 Yes No I don’t know 149 8 25 81.9 4.4 13.7 One dos Two doses I don’t know 89 49 44 48.9 26.9 24.2 Less than 9 years 9–14 years Can be provided at any age I don’t know 19 66 53 44 10.4 36.3 29.1 24.2 Yes NO 138 136 50.4 49.6 Yes No 119 155 43.4 56.6 Yes No 147 127 53.6 46.4 Yes No 261 13 95.3 4.7 Yes No 187 87 68.2 31.8 1 dose 2 doses 3 doses 121 42 24 64.7 22.5 12.8 Yes No 66 208 24.1 75.9 Yes No 66 55 54.5 45.5 Knowledge, attitudes, and information about HPV vaccine among female adolescents attending district Hospital ART clinic Table 2 above shows that most participants, 182 (66.4%), had heard of the HPV vaccine, and of those, 149 (81.9%) knew that the HPV vaccine is used to prevent HPV infection and cervical cancer. When asked about the recommended doses of the HPV vaccine, 49 (26.9%) identified that the recommended doses of the HPV vaccine, i.e. two or more doses, 89 (48.9%) one dose, and 44 (24.4%) didn’t know. While 66 (36.3%) knew the ideal age for HPV vaccine was between 9 and 14 years, 53 (29.1%) said that it could be provided at any age; about half 138 (50.4%) had received information about the HPV vaccine, and 119 (43.4%) had been taught about HPV or cervical cancer at school, 147 (53.6%), reported the availability of HPV awareness creation at school or in the community, and 261 (95.3%), agreed that they needed more information about the HPV vaccine. Figure 1 shows the attitudes of the respondents about the HPV vaccine. Most participants, 205 (74.8%), strongly agreed that it is important to receive the HPV vaccine, 62 (22.6%) agreed, and 3 (1.1%) disagreed. When asked whether they would accept to receive the HPV vaccine, 188 (68.6%) strongly agreed, 62 (22.6%) agreed, and 14 (5.1%) disagreed. Most participants (58.4%, n = 160) strongly agreed that their parents would permit them to receive the HPV vaccine, while 23.0% (n = 63) agreed. Additionally, 9.9% (n = 27) were neutral on the matter, 2.9% (n = 8) disagreed, and 5.8% (n = 16) strongly disagreed.In addition, 152 (55.5%) strongly agreed that their friends convinced them to receive the HPV vaccine, 70 (25.5%) agreed, 31 (11.3%) were neutral, 11 (4.0%) disagreed, and 10 (3.6%) strongly disagreed. Attitudes towards HPV vaccination Figure 2 shows the facilitators of HPV vaccination. Participants mentioned the main facilitators were having information 173 (63.1%), having enough vaccines 155 (56.6%), HPV vaccines being free of charge 113 (41.2%), recommendations from health workers 111(40.5%), and Parental or caretaker support toward HPV vaccination 106 (38.7%). Facilitators to uptake of HPV vaccination Figure 3 shows the barriers to HPV vaccination. Long distances to the vaccination sites 141 (51.5%), lack of knowledge and information about the HPV vaccine 112 (40.9%), negative attitudes towards the vaccine 109 (39.8%), Vaccine concerns about safety and effectiveness, misconceptions, and fear of side effects 93 (33.9%) were some of the barriers to receiving the HPV vaccine reported by the participants. Barriers to uptake of HPV vaccination Bivariate and multivariate regression results of factors associated with uptake of HPV vaccination among adolescents attending District Hospital ART clinic Table 3 shows the bivariate and multivariate analyses of factors associated with HPV vaccine uptake. The following were significantly associated with HPV uptake: Aadolescents who received the HPV vaccine were more likely to reside in urban centres (cOR 2.16, 95% CI 1.26–3.72, P = 0.005), to have ever heard of HPV vaccine (cOR 4.32, 95% CI 2.51–7.44, P = < 0.001), to have received information about HPV vaccine (cOR 5.73, 95% CI 3.20-10.24, P = < 0.01), or to have been taught about HPV vaccine and cervical cancer at school (cOR 10.80, 95% CI 5.33–22.11, P = < 0.001). Availability of awareness creation and campaigns about HPV vaccine (cOR 3.24, 95% CI 2.00-5.84, P = < 0.001), living within a distance of less than 5 km from the health facility (cOR 5.56, 95% CI 2.47–12.50, P = < 0.001), recommendation from health workers (cOR 3.55, 95% CI 2.02–6.22, P = < 0.001), and availability of HPV vaccines (cOR 9.981, 95% CI 4.57–21.81, P = < 0.001) were associated with HPV vaccine uptake. Table 3Bivariate and multivariate regression results of factors associated with uptake of HPV vaccination among adolescents attending the district Hospital ART clinicVariableUptake of HPV vaccinecOR (95% CI)P-valueAdjusted OR (95% CI)P-valueYESn= (187)n (%)NOn= (87)n (%) Socio-demographic characteristics Age (in years) 15–1920–2476 (40.6)111 (59.4)25 (28.7)62 (71.3)1.70 (0.98–2.94)Reference0.0582.88 (1.356.14)Reference 0.006 Religion CatholicAnglicanBorn againMuslim88 (47.1)46 (24.6)37 (19.8)16 (8.6)35 (40.2)19 (21.8)22 (25.3)11 (12.6)Reference0.87 (0.24–1.53)0.601 (0.27–1.53)0.59 (0.24–1.37)0.7600.2860.313 Tribe MugandaOthers148 (79.1)39 (20.9)69 (79.3)18 (20.7)Reference1.01 (0.54–1.89)0.975 Family type Nuclear familyExtended family130 (69.5)57 (30.5)57 (65.5)30 (34.5)1.20 (0.70–2.06)Reference0.508 Current education status At schoolOut of school82 (43.9)105 (56.1)28 (32.2)59 (67.8)1.65 (0.96–2.82)Reference0.068 Level of education No educationPrimary educationSecondary educationTertiary education9 (4.8)52 (27.8)118 (63.1)8 (4.3)10 (11.5)29 (33.3)45 (51.7)3 (3.4)Reference1.02 (0.26–4.01)1.49 (0.37–6.05)2.96 (0.60–14.73)0.1200.9810.579 Residence UrbanRural141(75.4)46(24.6)51(58.6)36(41.4)2.16 (1.26–3.72)Reference 0.005 1.20(0.59–2.43)Reference0.612 Employment status EmployedUnemployed172(92.0)15(8.0)75(86.2)12(13.8)1.84 (0.82–4.11)Reference0.14Knowledge, attitude and information about HPV vaccination Ever heard of HPV vaccine YesNo144 (77.0)43 (23.0)38(43.7)49(56.3)4.32 (2.51–7.44)Reference < 0.001 1.85(0.87–3.94)Reference0.110 Ever received information about HPV vaccine YesNo118 (63.1)69 (36.9)20 (23.0)67 (77.0)5.74 (3.20 − 10.24)Reference < 0.001 0.84 (0.32–2.25)Reference0.733 Taught about HPV or cervical cancer at school YesNo109 (58.3)78 (41.7)10 (11.5)77 (88.5)10.76 (5.34 − 22.11)Reference < 0.001 8.72 (2.77–24.73)Reference < 0.001 Availability of awareness creation about HPV or cervical cancer at school or community YesNo118(63.1)69(36.9)29 (33.3)58 (66.7)3.40 (2.00–5.84)Reference < 0.001 0.55 (0.19 1.64)Reference0.285 Health system factors Distance from home to the health facility 0–5 kms6–10 kmsMore than 10 kms130 (69.5)45 (24.1)12 (6.4)37 (42.5)31 (35.6)19 (21.8)5.56 (2.48–12.50)2.42 (1.35–4.35)Reference < 0.001 0.003 5.90 (2.16–16.12)4.16 ( 0.57 30.23)Reference 0.001 0.123 Health providers talk to you about HPV or cervical cancer YesNo100(53.5)87(46.5)23(26.4)64(73.6)3.20 (1.8–5.58)Reference < 0.001 0.06 (0.00-1.19)Reference0.064 Health providers recommend to you HPV vaccine YesNo102 (54.5)85 (45.5)22 (25.3)65 (74.7)3.55 (2.02–6.22)Reference < 0.001 4.83 (0.53–43.97)Reference0.162 Are HPV vaccines available in nearest health facility YesNo94 (50.3)93 (49.7)8 (9.2)79 (90.8)9.98 (4.57–21.81)Reference < 0.001 5.23 (1.89–14.51)Reference 0.001 Bivariate and multivariate regression results of factors associated with uptake of HPV vaccination among adolescents attending the district Hospital ART clinic 15–19 20–24 76 (40.6) 111 (59.4) 25 (28.7) 62 (71.3) 1.70 (0.98–2.94) Reference 2.88 (1.356.14) Reference Catholic Anglican Born again Muslim 88 (47.1) 46 (24.6) 37 (19.8) 16 (8.6) 35 (40.2) 19 (21.8) 22 (25.3) 11 (12.6) Reference 0.87 (0.24–1.53) 0.601 (0.27–1.53) 0.59 (0.24–1.37) 0.760 0.286 0.313 Muganda Others 148 (79.1) 39 (20.9) 69 (79.3) 18 (20.7) Reference 1.01 (0.54–1.89) Nuclear family Extended family 130 (69.5) 57 (30.5) 57 (65.5) 30 (34.5) 1.20 (0.70–2.06) Reference At school Out of school 82 (43.9) 105 (56.1) 28 (32.2) 59 (67.8) 1.65 (0.96–2.82) Reference No education Primary education Secondary education Tertiary education 9 (4.8) 52 (27.8) 118 (63.1) 8 (4.3) 10 (11.5) 29 (33.3) 45 (51.7) 3 (3.4) Reference 1.02 (0.26–4.01) 1.49 (0.37–6.05) 2.96 (0.60–14.73) 0.120 0.981 0.579 Urban Rural 141(75.4) 46(24.6) 51(58.6) 36(41.4) 2.16 (1.26–3.72) Reference 1.20(0.59–2.43) Reference Employed Unemployed 172(92.0) 15(8.0) 75(86.2) 12(13.8) 1.84 (0.82–4.11) Reference Yes No 144 (77.0) 43 (23.0) 38(43.7) 49(56.3) 4.32 (2.51–7.44) Reference 1.85(0.87–3.94) Reference Yes No 118 (63.1) 69 (36.9) 20 (23.0) 67 (77.0) 5.74 (3.20 − 10.24) Reference 0.84 (0.32–2.25) Reference Yes No 109 (58.3) 78 (41.7) 10 (11.5) 77 (88.5) 10.76 (5.34 − 22.11) Reference 8.72 (2.77–24.73) Reference Yes No 118(63.1) 69(36.9) 29 (33.3) 58 (66.7) 3.40 (2.00–5.84) Reference 0.55 (0.19 1.64) Reference 0–5 kms 6–10 kms More than 10 kms 130 (69.5) 45 (24.1) 12 (6.4) 37 (42.5) 31 (35.6) 19 (21.8) 5.56 (2.48–12.50) 2.42 (1.35–4.35) Reference < 0.001 0.003 5.90 (2.16–16.12) 4.16 ( 0.57 30.23) Reference 0.001 0.123 Yes No 100(53.5) 87(46.5) 23(26.4) 64(73.6) 3.20 (1.8–5.58) Reference 0.06 (0.00-1.19) Reference Yes No 102 (54.5) 85 (45.5) 22 (25.3) 65 (74.7) 3.55 (2.02–6.22) Reference 4.83 (0.53–43.97) Reference Yes No 94 (50.3) 93 (49.7) 8 (9.2) 79 (90.8) 9.98 (4.57–21.81) Reference 5.23 (1.89–14.51) Reference Multivariate logistic regression analysis found that uptake of HPV vaccination remained significant after controlling for respondent age 15 to 19 years (AOR 2.88, 95% CI 1.35–6.14, P = 0.006), taught about HPV vaccine and cervical cancer at school (AOR 8.72 95% CI 2.77–24.73, P = < 0.001), living within a distance of less than 5 km from the health facility (AOR 5.90, 95% CI 2.16–16.12, P = < 0.001), availability of HPV vaccines at the health facility (AOR 5.23, 95% CI 1.89–14.51, P = < 0.001) (Table 3 below). Bivariate and multivariate regression results of factors associated with completion of HPV vaccination among adolescents attending District Hospital ART clinic Bivariate analyses showed that adolescents who completed the HPV vaccine were more likely to be from the Baganda tribe (cOR 2.74, 95% CI 1.46–5.12, P = 0.002) availability of HPV vaccines at nearby health facilities (cOR 2.20, 95% CI 1.18–4.12, P = < 0.014) were statistically significant. Multivariate logistic regression analysis found that completion of HPV vaccination remained significantly associated with age 20 to 24 years (AOR 1.923, 95% CI 1.057–3.499, P = 0.032), and being a Muganda by tribe (AOR 2.20, 95% CI 1.13–4.28, P = 0.021) (Table 4 below). Table 4Bivariate and multivariate regression results of factors associated with completion of HPV vaccination among adolescents attending district Hospital ART clinicSocio-demographic characteristicCompletion of HPV vaccinecOR (95% CI)P-valueAOR (95%CI)P-valueNot fully vaccinatedn= (208)n (%)Fully vaccinatedn= (66)n (%)Age (in years)15–1970(33.7)31 (47.0)ReferenceReference20–24138(66.3)35 (53.0)1.746(0.95–3.06)0.0521.923(1.06–3.49)0.032 Religion Catholic99 (47.6)24 (36.4)ReferenceAnglicanBorn againMuslim50 (24.0)40 (19.2)19 (9.1)15 (22.7)19 (28.8)8 (12.1)1.13 (0.42–3.04)0.71 (0.26– 1.95)0.58 (0.23–1.47)0.8110.510.249 Tribe MugandaOthers174 (83.7)34 (16.3)43 (65.2)23 (34.8)2.74 (1.46–5.12)Reference 0.002 2.20 (1.13–4.28)References 0.021 Family type Nuclear familyExtended family147 (70.7)61 (29.3)40 (60.6)26 (39.4)1.57 (0.880 − 2.79)Reference0.1271.41(0.75–2.64)Reference0.284 Current education status At schoolOut of school81 (38.9)127 (61.1)29 (43.9)37 (56.1)0.81 (0.46–1.43)Reference0.471 Level of education No educationPrimary educationSecondary educationTertiary education16 (7.7)62 (29.8)123 (59.1)7 (3.4)3 (4.6)19 (28.8)40 (60.6)4 (6.1)Reference0.56 (0.16–2.04)0.54(0.142 − 2.03)0.33 (0.06 − 1.87)0.3880.3590.210 Residence UrbanRural150(72.1)58(27.9)42(63.6)24(36.4)1.48 (0.82– 2.65)Reference0.1911.12(0.59-2.)0Reference0.724 Employment status EmployedUnemployed187 (89.9)21 (10.1)60 (90.9)6 (9.1)0.890 (0.343– 2.309)Reference0.811 Ever heard of the HPV vaccine? YesNo140 (67.3)68 (32.7)42 (63.6)24 (36.4)1.18 (0.65– 2.10)Reference0.582 Have you ever received information about the HPV vaccine? YesNo107 (51.4)101 (48.6)31 (47.0)35 (53.0)1.19 (0.69 − 2.08)Reference0.527 Availability of awareness creation about HPV or cervical cancer at school or community YesNo113(54.3)95 (45.7)34 (51.5)32 (48.5)1.120 (0.643–1.949)Reference0.690 Distance from home to the health facility 0–5 kms6–10 kmsMore than 10 kms126 (60.6)59 (28.4)23 (11.1)41 (62.1)17 (25.8)8 (12.1)1.07 (0.44–2.57)0.89 (0.46–1.69)Reference0.8820.711 Health providers talk to you about HPV or cervical cancer YesNo97(46.6)111(53.4)27(40.9)39(59.1)1.26 (0.72–2.21)Reference0.416 Health providers provide you with information about HPV or cervical cancer YesNo96(46.2)112(53.8)27(40.9)39(59.1)1.238 (0.706–2.170)Reference0.456 Health providers recommend to you HPV vaccine YesNo96 (46.2)112 (53.8)28 (42.4)38 (57.6)1.16 (0.66–2.03)Reference0.596 Are HPV vaccines available in nearest health facility YesNo86 (41.3)122 (58.7)16 (24.2)50 (75.8)2.20 (1.18–4.12)Reference 0.014 1.70(0.86–3.36)Reference0.127 Bivariate and multivariate regression results of factors associated with completion of HPV vaccination among adolescents attending district Hospital ART clinic Not fully vaccinated n= (208) n (%) Fully vaccinated n= (66) n (%) Anglican Born again Muslim 50 (24.0) 40 (19.2) 19 (9.1) 15 (22.7) 19 (28.8) 8 (12.1) 1.13 (0.42–3.04) 0.71 (0.26– 1.95) 0.58 (0.23–1.47) 0.811 0.51 0.249 Muganda Others 174 (83.7) 34 (16.3) 43 (65.2) 23 (34.8) 2.74 (1.46–5.12) Reference 2.20 (1.13–4.28) References Nuclear family Extended family 147 (70.7) 61 (29.3) 40 (60.6) 26 (39.4) 1.57 (0.880 − 2.79) Reference 1.41(0.75–2.64) Reference At school Out of school 81 (38.9) 127 (61.1) 29 (43.9) 37 (56.1) 0.81 (0.46–1.43) Reference No education Primary education Secondary education Tertiary education 16 (7.7) 62 (29.8) 123 (59.1) 7 (3.4) 3 (4.6) 19 (28.8) 40 (60.6) 4 (6.1) Reference 0.56 (0.16–2.04) 0.54(0.142 − 2.03) 0.33 (0.06 − 1.87) 0.388 0.359 0.210 Urban Rural 150(72.1) 58(27.9) 42(63.6) 24(36.4) 1.48 (0.82– 2.65) Reference 1.12(0.59-2.)0 Reference Employed Unemployed 187 (89.9) 21 (10.1) 60 (90.9) 6 (9.1) 0.890 (0.343– 2.309) Reference Yes No 140 (67.3) 68 (32.7) 42 (63.6) 24 (36.4) 1.18 (0.65– 2.10) Reference Yes No 107 (51.4) 101 (48.6) 31 (47.0) 35 (53.0) 1.19 (0.69 − 2.08) Reference Yes No 113(54.3) 95 (45.7) 34 (51.5) 32 (48.5) 1.120 (0.643–1.949) Reference 0–5 kms 6–10 kms More than 10 kms 126 (60.6) 59 (28.4) 23 (11.1) 41 (62.1) 17 (25.8) 8 (12.1) 1.07 (0.44–2.57) 0.89 (0.46–1.69) Reference 0.882 0.711 Yes No 97(46.6) 111(53.4) 27(40.9) 39(59.1) 1.26 (0.72–2.21) Reference Yes No 96(46.2) 112(53.8) 27(40.9) 39(59.1) 1.238 (0.706–2.170) Reference Yes No 96 (46.2) 112 (53.8) 28 (42.4) 38 (57.6) 1.16 (0.66–2.03) Reference Yes No 86 (41.3) 122 (58.7) 16 (24.2) 50 (75.8) 2.20 (1.18–4.12) Reference 1.70(0.86–3.36) Reference Discussion In this study of adolescent girls and young women living with HIV attending an ART clinic in Uganda, we found that while HPV vaccine initiation was relatively high at 68.2%, completion of the recommended two or more doses was notably low at 24.1%. Initiation of HPV vaccination was significantly associated with being aged 15–19 years, receiving education about HPV and cervical cancer at school, living within 5 km of the health facility, and the availability of the vaccine at the clinic. In contrast, completion of the vaccine series was more likely among participants aged 20–24 years. HIV-positive girls require HPV vaccination due to the increased risk of contracting the virus and decreased risk of eliminating the viral infection, thus increasing the risk of developing HPV-related illnesses and malignancies. Despite antiretroviral therapy, HIV-positive individuals’ immune responses may be suboptimal, making HPV vaccination crucial for protecting them against HPV-related risks. Therefore, this study aimed to assess the factors associated with HPV vaccination uptake and completion among HIV-positive young girls. The initiation and completion of HPV vaccination among HIV-positive girls are both crucial for preventing HPV-related diseases and cervical cancer. In this study, about 68% initiated HPV vaccination, but the completion rate was very low (24%). This is low compared to the World Health Organisation (WHO), which set goal to eradicate cervical cancer by 2030, aiming to have 90% of girls fully vaccinated with the HPV vaccine by age 15 [28]. This is very low compared to a study conducted in the United States, which reported completion rates of about 60% [29]. Reduced protection against HPV infection is one consequence of poor completion rates; this, in turn, can raise the risk of HPV-related illnesses like cervical cancer [13]. Because of their increased vulnerability to HPV-related health consequences, high-risk populations, such as HIV-positive girls, should prioritise HPV vaccination as a preventive intervention. The optimal protection against HPV-related malignancies and illnesses is ensured by completing the HPV vaccine series. To improve the chances of preventing cervical cancer and other HPV-related illnesses among HIV-positive girls, interventions should be implemented to strengthen social mobilisation, outreach, vaccination strategies, and education to increase vaccine uptake. Knowledge of HPV is crucial in determining the uptake and completion of the vaccine [30]. Low knowledge about HPV vaccination, particularly among adolescents, can lead to misconceptions and hinder its effectiveness, affecting the uptake and utilisation of vaccination programs [31, 32]. In this study, we found that 66.4% of participants knew about the HPV vaccine; 81.9% knew it prevented infection and cervical cancer. However, only 26.9% knew the recommended doses, and 36.3% knew the ideal age for the vaccine (9–14 years). Furthermore, adolescents who heard about the HPV vaccine were four times more likely to receive it, and those who received information about it were six times more likely to take up the vaccine. In an Ethiopian study of female students enrolled in preparatory schools, those who knew a lot about the HPV vaccine had a 2.36-fold higher chance of getting it than those who knew very little [30]. The decision-making process for HPV vaccination among young people is greatly influenced by their level of HPV knowledge [33]. Research shows that young adults and adolescents do not understand human papillomavirus (HPV) and how to prevent it through vaccination [4, 34]. To ensure increased HPV vaccine completion, it is crucial to raise awareness among school nurses and caregivers and enhance information about HPV and its benefits. Residence plays a significant role in HPV vaccination uptake. In this study, young people living in urban centres were more likely to take up the HPV vaccine. This could be attributed to urban areas having better healthcare access [35], higher awareness of HPV vaccination [35], and community outreach programs [35]. Also, adolescents living in urban centres are exposed to media that provides information on the HPV vaccine and its importance, leading to higher vaccination rates among adolescents. To close the gap in HPV vaccination rates between rural and urban areas, targeted initiatives and better healthcare facility accessibility are required. Schools play a critical role in promoting HPV vaccination and reducing HPV-related diseases. This study revealed that adolescents who were educated about the HPV vaccine and cervical cancer at school were five times more likely to receive the vaccine. This could be attributed to the fact that schools provide access to many adolescents, are convenient for families, and encourage peer support for vaccination [36]. School-based vaccination programs have positively influenced parents’ attitudes towards HPV vaccination [37]. School nurses play a crucial role in promoting HPV vaccination among children and adolescents by providing education, encouragement, and administration of the vaccine series. Although schools offer a chance to get vaccinated, it could also pose a problem for teenagers living with HIV who need to take more doses than their non-immune-compromised peers. Stigmatisation may result from this. To accommodate immunocompromised teenagers, it is necessary to provide many locations that may be utilised for HPV vaccination. Increasing the rate of HPV vaccination among young people and adolescents who are HIV positive can be achieved through the integration of this vaccine into antiretroviral treatment clinics. Promoting and providing the HPV vaccine is an important responsibility of healthcare workers. The research found that healthcare professionals’ advice significantly increased the HPV vaccine adoption rate among adolescents by four times. Health workers are crucial in recommending HPV vaccination to patients [38, 39], providing education and support, and addressing misconceptions [38, 39]. Effective patient-provider communication is key for successful vaccination programs and optimal coverage rates [39]. Healthcare workers need to undergo training, education, and community-based outreach programs. The distance from home to the vaccination location significantly influences HPV vaccine uptake. In this study, we found that adolescents living within a distance of less than 5 km from the health facility were more likely to take the HPV vaccine. These results are similar to studies done; these findings coincide with the findings found in the Kabarole and Lira district in Uganda [40, 41], which found that longer distances associated with poor transport networks are known to hinder individuals from accessing services at health facilities to receive health services. Improving access and uptake can be achieved by bringing immunisation services closer to where girls live, for example, through ART Clinics. One important factor in determining the rate of HPV uptake is the accessibility of HPV vaccinations. In this study, the availability of HPV vaccines was found to increase the HPV vaccine uptake among adolescents living with HIV by ten times. Research shows that more people will get the HPV vaccine if it is available at the injection location. Having vaccines on hand at the injection location, according to one study in South Michigan, raised uptake from 11% to 16% [35]. Higher HPV vaccine uptake was also linked to outreach immunisation techniques and the availability of sufficient vaccinations, according to a Ugandan study [35]. This is because vaccine availability in convenient places or clinics reduces travel time and costs as it also creates a sense of vaccination importance and is readily accessible, which increases the uptake. There is a need to consider ART clinics, community outreach programs, and school-based initiatives as among the methods that have been proposed to increase vaccine accessibility. A person’s age is a major factor in whether or not they get an HPV vaccine. The main target age group for HPV vaccination, according to the World Health Organization (WHO), should be 9–14 years old, with an emphasis on vaccinating girls before their sexual activity. In this study, adolescents aged 15- to 19-year-olds were more likely to uptake the vaccine than those above 19 years. This is contrary to some studies that found that older adolescents, particularly those aged 16–18 years, showed higher HPV vaccination uptake compared to younger age groups 14–15 years [42]. This could be explained by the fact that the HPV vaccination is primarily recommended for pre-adolescent and adolescent girls, specifically targeting those aged 9–14 years who are in school, and the immunisation mainly occurs in schools. The rate of HPV vaccine uptake differs with age, according to the studies. For instance, a Ugandan study indicated that compared to females aged 9–14, HPV vaccination uptake was lower among girls aged 15–18 [40, 43]. Addressing these age-related disparities in HPV vaccination will be crucial for improving population-level coverage and cancer prevention. Limitations Firstly, the study’s cross-sectional nature limits its ability to prove a causal link between the identified factors and the uptake or completion of the HPV vaccine. Additionally, it was conducted in a single ART clinic, which might restrict the applicability of the findings to other environments or to HIV-positive adolescents who are not in regular care. Some data were based on self-reports, which could introduce potential recall and social desirability biases. The study primarily examined individual and facility-level factors without considering the health system’s or community’s broader influences. Lastly, the exclusion of males and younger adolescents means that the results cannot be generalised to all young people living with HIV. Conclusion The initiation and completion of HPV vaccination among HIV- positive girls are both crucial for preventing HPV related diseases and cancers. In this study the completion rate is very low. Vaccination against human papillomavirus (HPV) must be prioritised in the HIV-positive youth population. The findings suggest a need for targeted policies to improve vaccine uptake among HIV-positive youth, including better education, healthcare provider engagement, and system support for follow-up care. This will guide targeted interventions in achieving the WHO’s target of 90% immunising all adolescent girls by 2030. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors would like to thank the adolescents and young people in all the facilities where we collected data, the research assistants, and the funders for this work. Author contributions SNM designed the study, collected and analysed the data, and drafted the paper; AS, JH, MS, DKK, and MN contributed to the study’s design and reviewed the paper. DAL contributed to collecting data, analysing, and reviewing the paper. All the authors approved the final draft of the paper. Funding Fred Ssewamala and Mary Mckay received the ACHIEVE award from NIH. SNM received an award from the ACHIEVE program. The National Institute of Health’s Fogarty International Center (FIC) supports the ACHIEVE Program. Grant Number D43 (TW012275-01). The content is solely the authors’ responsibility and does not necessarily represent the official views of the National Institutes of Health. Data availability The acquired and/or analysed data are not publicly available because of the lack of authorisation from the children’s legal guardians and the agreement with the Research Ethics Committee that the database would remain with the corresponding author only. However, the corresponding author can make all data available upon reasonable request. Declarations Ethics approval and consent to participate Ethical reviews and approval were obtained from the Research Ethics Committee of the School of Health Sciences, College of Health Sciences at Makerere University (#MAKSHSREC-2023-611) and the Uganda National Council for Science and Technology (HS3685ES). Administrative clearance and permissions were also obtained from the management of Mityana General Hospital. Written informed consent was obtained from young people 18 years and above. For adolescents below 18 years, assent from the adolescents and consent from parents or guardians was obtained. Participation was voluntary, and all the interviews were conducted in private settings to ensure the confidentiality of the participants, and participation was voluntary. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The acquired and/or analysed data are not publicly available because of the lack of authorisation from the children’s legal guardians and the agreement with the Research Ethics Committee that the database would remain with the corresponding author only. However, the corresponding author can make all data available upon reasonable request.